FendX and Aquaox Enter into Collaboration Agreement to Pursue Innovation in Eco-Friendly Antimicrobial Agents

Executive Summary

• FendX Technologies Inc. entered into a formal collaboration agreement with Aquaox LLC to assess technical feasibility of antimicrobial agents.
• The initial phase focuses on evaluating formulation capabilities; costs are borne by each party and the agreement includes termination provisions.
• Successful completion could lead to further agreements for developing novel antimicrobial products for healthcare, consumer, and commercial markets.

Key Details

• Agreement Date: January 20, 2026.
• Parties: FendX Technologies Inc. (CSE: FNDX) and Aquaox LLC (U.S. manufacturer of environmentally responsible disinfectants).
• Scope – Phase 1:
• Assess technical feasibility of formulating antimicrobial agents using FendX’s technology.
• Confirm ability to reliably produce such agents for potential product development.
• Potential Next Steps: Upon successful feasibility, parties may negotiate definitive agreements to develop and commercialize novel antimicrobial products.
• Cost Allocation: Each party is responsible for its own costs and expenses incurred under the agreement.
• Termination Provisions: The agreement contains standard termination rights for either party.
• Risk Disclosures: No assurance that collaboration will progress beyond feasibility, result in regulatory approvals, or lead to commercial products; subject to technical, regulatory, and additional agreement considerations.
• Previous Relationship: Builds on a Memorandum of Understanding announced November 18, 2025.

Notable Quotes

• “We are pleased to formalize this collaboration, which represents a meaningful next step in our relationship with Aquaox,” – Dr. Carolyn Myers, CEO, FendX Technologies Inc.
• “Formalizing this agreement provides a framework to evaluate the feasibility and performance of our antimicrobial technology in collaboration with FendX,” – Michel van Schaik, CEO, Aquaox LLC.